Market Performance of Shenqi Pharmaceutical on 27 August 2026

On 27 August 2026 the Shanghai Stock Exchange witnessed a vigorous rally, with the Shanghai Composite Index rising 1.13 % to 3,956.57 points. Amid this broader positive sentiment, Shenqi Pharmaceutical (600613) stood out as a pre‑eminent performer. The shares achieved a 10.05 % intraday gain, setting a new personal record and confirming the company’s position as the leading gain‑maker of the day.

Record‑Breaking Trading Volume

At 14:42 h the stock’s trading volume reached 15.02 亿元, the highest since 21 November 2022. This surge was accompanied by a turnover‑rate of 32 %, indicating that a large portion of the shareholder base was active. Compared to the previous day’s 9.38 亿元, the volume rose by roughly 60 %, underscoring heightened investor interest.

Long‑Term Consolidation: 11‑Day, 7‑Board History

Shenqi’s performance is not an isolated event. The share has been on a continuous up‑trend for 11 days, achieving seven consecutive price‑limit‑up (板) sessions. Such a streak is rare in the A‑share market, and it places the company at the forefront of the daily “强势个股” (strong stocks) list. This sustained momentum has been confirmed by multiple market‑watch reports:

  • “神奇制药11天7板” (Shenqi Pharmaceutical 11 days, 7 boards) appears repeatedly across midday and closing market summaries.
  • The company’s board history has also been highlighted in the context of other long‑standing streaks, such as 金健米业 (9 days, 6 boards) and 深中华A (6 days, 6 boards), illustrating a broader trend of momentum stocks in the Chinese market.

Sector Context and Conceptual Themes

Shenqi’s success aligns with the broader rise in the “存储芯片” (storage chip) and “CPO” (co‑packaging optics) concepts, which dominated the daily sector performance. While those segments led the overall market, the pharmaceutical sector also benefited from a resurgence in CRO (contract‑research‑organization) and innovation‑drug themes. In particular, the “创新药” (innovative drug) sector saw gains in other peers such as 汉森制药 (Hansen Pharmaceuticals) and 华森制药 (Wason Pharmaceuticals), signalling a healthy environment for pharma stocks.

Company Fundamentals

  • Market Capitalisation: 5,426,167,296 CNY
  • Closing Price (25 Aug 2026): 10.55 CNY
  • 52‑Week High/Low: 10.56 CNY / 4.33 CNY
  • PE Ratio: 162.26

The company’s valuation remains high, a reflection of investor expectations that its recent trading activity will translate into sustained earnings growth. The Price‑to‑Earnings ratio of 162.26 is indicative of strong optimism about future profitability, especially given the firm’s position within a rapidly expanding pharmaceutical market in China.

Market Sentiment and Analyst Outlook

The market’s overall sentiment on 27 August was buoyant, with 77 stocks hitting the daily price ceiling and a transaction volume of 2.13 trillion CNY – an increase of 3.172 billion CNY from the previous day. Shenqi’s performance contributed to this trend, and analysts noted that the company’s 11‑day streak could signal a new “bullish cycle” in the pharmaceutical sector.

In summary, Shenqi Pharmaceutical’s 10.05 % rise on 27 August, combined with a record trading volume and an extended board‑streak, underscores its prominence within a broader market rally. The firm’s robust fundamentals and the positive momentum in related concepts suggest that the stock remains a focal point for investors seeking exposure to China’s fast‑growing healthcare sector.